secwatch / observer
8-K filed May 18, 2026, 5:00 PM ET ticker SLN CIK 0001479615
other material confidence high sentiment positive materiality 0.65

Silence Therapeutics enters new ATM with Jefferies; says not PFIC for 2025

Silence Therapeutics plc

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Silence Therapeutics plc terminated Prior Sales Agreement with Jefferies LLC (effective 2026-05-18).

Action
termination
Agreement
atm program
Counterparty
Jefferies LLC
Effective
2026-05-18
Exact text from the filing
The Sales Agreement replaces the prior Open Market Sale Agreement SM , dated October 15, 2021, by and between the Company and Jefferies (the “Prior Sales Agreement’), which was terminated as of May 18, 2026 pursuant to the terms of the Sales Agreement.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Silence Therapeutics plc entered into Sales Agreement with Jefferies LLC valued at aggregate offering amount not exceeding the Maximum Program Amount (effective 2026-05-18).

Action
entry
Agreement
atm program
Counterparty
Jefferies LLC
Value
aggregate offering amount not exceeding the Maximum Program Amount
Effective
2026-05-18
Exact text from the filing
On May 18, 2026, Silence Therapeutics plc (the “Company” or “we”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”).
View on SEC.gov

Browse all material agreements →

Silence Therapeutics plc filing history →

Source: SEC EDGAR
accession 0001193125-26-229089
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.